Through more than 20 years of accumulated commercialization experience, MEDIPOST has built proven execution capabilities in large-scale cell culture process development and technology transfer.
Process design and optimization capability with scale-up in mind
Ability to execute rapid technology transfer connecting early development to production
A reproducibility-focused manufacturing system that ensures batch-to-batch consistency
This enables us to help our clients’ technology move beyond the research stage into actual production and commercialization.
Scale-up
MEDIPOST’s scale-up strategy is not simply about increasing production volume — it is designed as a three-stage management system that reproducibly scales up to commercial production volume while preserving cell characteristics.
Scale-up Risk Management Strategy:
1. Initial verification in a predictable small-scale model
– Scale-down model validation
2. Secondary verification through stepwise expansion
– Maintaining biological comparability
– Incorporating large-scale culture vessels (CellSTACK 10-Layer, HYPERStack 36-Layer)
3. Tertiary verification at commercial batch scale
– Process validation
Fast-track Tech Transfer
MEDIPOST’s Fast-track Tech Transfer approach uses a risk-management framework to compress a technology transfer timeline that typically takes 12+ months down to within 9 months.
